<DOC>
	<DOCNO>NCT02731820</DOCNO>
	<brief_summary>The purpose study investigate whether use alkali compound , i.e . potassium citrate ( K3C6H5O7 , hereinafter KCitr ) effective prevent progression osteopenia . A randomized clinical trial ( RCT , placebo-controlled , double-blind ) plan evaluate effect daily administration KCitr ( 3 g/die , K 30 mEq ) . The efficacy evaluate compare circulating level bone turnover marker baseline treatment ( 3 , 6 month ) .</brief_summary>
	<brief_title>Efficacy Potassium Citrate Treatment Postmenopausal Osteopenia</brief_title>
	<detailed_description>Bone tissue carry important metabolic function , include regulation acid-base balance . In order buffer systemic acidosis , skeleton act `` ion exchange column '' modify composition mineral portion , i.e . hydroxyapatite . There linear correlation elimination calcium acidosis : high acidosis , high loss calcium bone . In vitro experiment show acidosis also directly influence cellular component bone increase osteoclast activity inhibit production mineralize matrix osteoblast . Since low pH risk factor accelerate bone loss , use alkalize compound could prevent osteopenia support conventional therapy osteoporosis . KCitr alkaline compound may use metabolic acidosis . Potassium alkaline metal play pivotal role function live cell . Citric acid key molecule Krebs cycle , abundant bone exhibit stabilize function . Although clinical data regard KCitr effectiveness calcium metabolism encouraging , still unclear whether beneficial effect due exclusively buffer function whether KCitr may affect bone cell activity . The purpose study evaluate effect KCitr bone metabolism . We hypothesize administration potassium citrate postmenopausal woman osteopenia delay ( prevent ) weaken bone mass . Postmenopausal woman osteopenia ( T score -1.0 -2.5 ) history fracture randomize assume KCitr ate placebo , daily six month . Primary outcomes evaluate measure marker bone turnover , measure baseline ( treatment ) , mid term ( 3 month ) end ( 6 month ) .</detailed_description>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<mesh_term>Potassium Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Postmenopausal woman , 5 year post menopause Osteopenia ( Tscore &lt; 1 &gt; 2.5 ) Low risk fracture ( FRAX : &lt; 20 major osteoporotic ; &lt; 3 hip fracture ) Hyperkalemia Renal insufficiency Nephrolithiasis Use potassium spar diuretic Use potassium supplement Use therapy influence bone metabolism ( e.g . corticosteroid , thiazide diuretic , aromatase inhibitor , estrogen ) Use protonic pump inhibitor Current recent use bisphosphonates ( stop less three year prior start study ) Gastrointestinal disorder hamper nutrient absorption ; Mental psychiatric disorder preclude possibility correctly adhere protocol</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>potassium citrate</keyword>
</DOC>